Clinical data shows low incidence rates
Obtain a Detailed Prescription: Ensure the prescription clearly states the diagnosed condition and the medical reason for semaglutide
Patients with pre-existing atrial fibrillation, structural heart disease, or conduction abnormalities should have baseline ECG and electrolyte panels before starting tirzepatide
Nathalia Souza, a 37-year-old from New Jersey, started taking tirzepatide after three years of dieting and exercising resulted in just 30 pounds of weight loss
Key findings across the STEP trials: Average weight loss of ~15% of body weight roughly 15 kg (33 lbs) for a 100 kg (220 lb) person 87% of patients lost at least 5% of body weight, compared to 31% on placebo Nearly 70% of patients lost at least 10% of body weight About 1 in 3 patients lost 20% or more Weight loss was maintained throughout the treatment period with continued medication use Significant improvements in blood pressure, blood sugar, cholesterol, and inflammatory markers alongside weight loss These results are dramatically better than any prior weight loss medication
Increased Quality of Life For many individuals struggling with obesity, losing weight is not just about aesthetics but also about improving overall health and quality of life
-1781043799568-1781071392919.png)
